BC
NVCR icon

Barrett & Company’s NovoCure NVCR Stock Holding History

Barrett & Company’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-40
Closed -$646 – 632
2023
Q3 		$646 Hold
40
– – ﹤0.01% 594
2023
Q2 		$1.66K Hold
40
– – ﹤0.01% 543
2023
Q1 		$2.4K Hold
40
– – ﹤0.01% 500
2022
Q4 		$2.93K Hold
40
– – ﹤0.01% 487
2022
Q3 		$2.93K Buy
+40
New +$3.12K ﹤0.01% 487

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barrett & Company's NVCR Position: Q4 2023 in Review

Barrett & Company sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 40 shares — an estimated $646 sold.

Barrett & Company first reported a position in NVCR in Q3 2022 and held it in 5 quarters. The position peaked at $2.93K in Q4 2022. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Barrett & Company reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Barrett & Company sold 40 NovoCure shares in Q4 2023, an estimated $646.
  • Barrett & Company first reported a position in NovoCure in Q3 2022 and held it in 5 quarters.
  • Barrett & Company's NovoCure position peaked at $2.93K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Barrett & Company's 13F filing for Q4 2023, filed 24 Jan 2024.